DE3770915D1 - Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli. - Google Patents

Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.

Info

Publication number
DE3770915D1
DE3770915D1 DE8787309318T DE3770915T DE3770915D1 DE 3770915 D1 DE3770915 D1 DE 3770915D1 DE 8787309318 T DE8787309318 T DE 8787309318T DE 3770915 T DE3770915 T DE 3770915T DE 3770915 D1 DE3770915 D1 DE 3770915D1
Authority
DE
Germany
Prior art keywords
sequence
protein
variant
expressed
escherichia coli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787309318T
Other languages
English (en)
Inventor
Rolando Lorenzetti
Lucia Monaco
Marco Soria
Raffaele Palomba
Antonella Isacchi
Paolo Sarmientos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL filed Critical Farmitalia Carlo Erba SRL
Application granted granted Critical
Publication of DE3770915D1 publication Critical patent/DE3770915D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE8787309318T 1986-10-23 1987-10-21 Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli. Expired - Fee Related DE3770915D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868625435A GB8625435D0 (en) 1986-10-23 1986-10-23 Human apolipoprotein ai

Publications (1)

Publication Number Publication Date
DE3770915D1 true DE3770915D1 (de) 1991-07-25

Family

ID=10606217

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787309318T Expired - Fee Related DE3770915D1 (de) 1986-10-23 1987-10-21 Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.

Country Status (16)

Country Link
EP (1) EP0267703B1 (de)
JP (2) JP2706247B2 (de)
KR (1) KR890700163A (de)
CN (1) CN87107991A (de)
AT (1) ATE64619T1 (de)
AU (1) AU8230587A (de)
CZ (1) CZ761587A3 (de)
DE (1) DE3770915D1 (de)
ES (1) ES2044950T3 (de)
GB (1) GB8625435D0 (de)
IL (1) IL84229A0 (de)
NO (1) NO882763L (de)
PT (1) PT85977B (de)
WO (1) WO1988003166A1 (de)
YU (1) YU193887A (de)
ZA (1) ZA877911B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712540D0 (en) * 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
GB8717791D0 (en) * 1987-07-28 1987-09-03 Baralle F E Immunoassay method
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
AU662885B2 (en) * 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5292646A (en) * 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
EP0516443A1 (de) * 1991-05-31 1992-12-02 Eli Lilly And Company Vektoren und Verfahren um die Regulation von Apolipoprotein-AI-Synthese zu Testen
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP2343317A1 (de) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein-konstrukte
IL161110A0 (en) 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
AP2006003578A0 (en) * 2003-10-20 2006-04-30 Esperion Therapeutics Inc Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes.
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
US7759315B2 (en) 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
EP2465519B1 (de) 2007-03-01 2013-10-23 CSL Limited Behandlung von endothelialer Dysfunktion bei Diabetes-Patienten
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
CA2826158A1 (en) 2011-02-07 2012-08-16 Rose ACKERMANN Lipoprotein complexes and manufacturing and uses thereof
CN112940090B (zh) * 2021-03-18 2023-02-24 广州康盛生物科技股份有限公司 耐受辐照灭菌及高效消毒的蛋白a免疫吸附介质

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217822B1 (de) * 1985-02-13 1993-05-12 Scios Nova Inc. Menschlicher metallothionein ii-promotor in säugetierexpressionssystemen

Also Published As

Publication number Publication date
JPH02500797A (ja) 1990-03-22
GB8625435D0 (en) 1986-11-26
JP2777126B2 (ja) 1998-07-16
JPH1052287A (ja) 1998-02-24
WO1988003166A1 (en) 1988-05-05
IL84229A0 (en) 1988-03-31
AU8230587A (en) 1988-05-25
ATE64619T1 (de) 1991-07-15
CZ761587A3 (en) 1994-11-16
PT85977B (en) 1990-01-19
EP0267703B1 (de) 1991-06-19
EP0267703A1 (de) 1988-05-18
YU193887A (en) 1989-06-30
KR890700163A (ko) 1989-03-10
ZA877911B (en) 1988-04-25
PT85977A (en) 1987-11-01
NO882763L (no) 1988-08-22
ES2044950T3 (es) 1994-01-16
CN87107991A (zh) 1988-09-21
NO882763D0 (no) 1988-06-22
JP2706247B2 (ja) 1998-01-28

Similar Documents

Publication Publication Date Title
DE3770915D1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
CA2168429A1 (en) Expression of fusion polypeptides transported out of cytoplasm without leader sequences
ZA885764B (en) Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology,process,expression vector and recombinant host therefor and pharmaceutical use thereof
DK0737207T3 (da) Inhibitorer for humant plasmin afledt af Kunitz-domæner
NO168538C (no) Fremgangsmaate for fremstilling av humant leukocytt-interferon av typen ifn-alfa 2(arg) ved hjelp av mikroorganismer som koder for disse.
DK3688D0 (da) Pankreatisk sekretorisk trypsininhibitor og varianter deraf fremstillet af en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert samt farmaceutisk anvendelse deraf
ATE103931T1 (de) Polypeptide aus vipergift und deren genexpression.
DE69331501D1 (de) Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
DK0434605T3 (da) Ny fremgangsmåde til fremstilling af ikke-fusioneret protein i E.coli
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
YU61893A (sh) Modifikovani faktor-4 krvnih pločica
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
ATE174963T1 (de) Klonierung und expression eines rhoptry- assoziierten proteins aus p. falciparum
DE3876227D1 (de) Malaria-spezifische dna-sequenzen, ihre expressionsprodukte und deren verwendung.
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA S.P.A., MAILAND/MILANO, IT

8339 Ceased/non-payment of the annual fee